Pages that link to "Item:Q5254712"
From MaRDI portal
The following pages link to Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials (Q5254712):
Displaying 20 items.
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer (Q70258) (← links)
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials (Q512445) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity (Q2441853) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803) (← links)
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
- Robust EM Continual Reassessment Method in Oncology Dose Finding (Q3111177) (← links)
- Continual reassessment method with multiple toxicity constraints (Q3303685) (← links)
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
- A new design of the continual reassessment method (Q5082671) (← links)
- Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
- PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials (Q6047779) (← links)
- Bayesian Model Averaging: A Systematic Review and Conceptual Classification (Q6086545) (← links)
- A continual reassessment method without undue risk of toxicity (Q6171847) (← links)
- A simulation-free approach to assessing the performance of the continual reassessment method (Q6617412) (← links)
- ComPAS: a Bayesian drug combination platform trial design with adaptive shrinkage (Q6625925) (← links)
- A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design (Q6628100) (← links)
- Commentary on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629386) (← links)